Fact checked by Nick Blackmer Atopic dermatitis, commonly referred to as eczema, has been a part of my life for as long as I ...

Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

Atopic dermatitis (AD) is a chronic inflammatory skin disease with high prevalence, especially in children. Current ...

Some patients with atopic dermatitis who qualify for advanced systemic therapies do not receive them or may lack improvement with these therapies.

Medically reviewed by William Truswell, MD Atopic dermatitis (the most common form of eczema) causes dry, itchy skin, often ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

A group of researchers have created four novel laboratory-developed tests that can distinguish between and subclassify atopic ...

Learn how ultrafine bubble showers can improve eczema symptoms by reducing inflammation and enhancing skin barrier proteins.

Panelists discuss how ruxolitinib cream demonstrated significant clinical efficacy in treating atopic dermatitis over a 12-month period, with claims analysis revealing improved disease control, ...

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

In a video interview with Healio, Benjamin N. Ungar, MD, discussed the risk factors of atopic dermatitis and the comorbidities associated with the condition.